Skip to search formSkip to main contentSkip to account menu

MGCD265

Known as: TKI MGCD265 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
Philadelphia (Ph*)/BCR-ABL1-positive chronic myeloid leukemia (CML) is considered as a chronic life-long disease, which could be… 
2019
2019
Novel Therapeutic Anti-ADAM17 Antibody A9(B8) Enhances EGFR-TKI–Mediated Anticancer Activity in NSCLC
2017
2017
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing
Tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are effective against lung adenocarcinomas harboring epidermal… 
2017
2017
Gefitinib or erlotinib in previously treated non–small‐cell lung cancer patients: a cohort study in Taiwan
Among treatment modalities for lung cancer, the most promising therapy is the use of epidermal growth factor receptor tyrosine… 
Highly Cited
2016
Highly Cited
2016
Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
There is a vital need for improved therapeutic strategies that are effective in both primary and metastatic triple-negative… 
2012
2012
Abstract 1790: The combination of MGCD265, a Met/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis
MGCD265 is an oral, multitargeted, receptor tyrosine kinase inhibitor in clinical development. MGCD265 targets the Met, VEGFR1, 2… 
Review
2012
Review
2012
Targeting the Met pathway in lung cancer
Dysregulation of Met signaling has been implicated in the initiation, progression and metastasis of human cancers, and therefore… 
2010
2010
Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.
e13595 Background: Therapeutics used to treat patients with NSCLC include cytotoxic agents such as taxanes, and targeted agents… 
2009
2009
Phase I study of daily administration of MGCD265 to patients with advanced malignancies (Study 265-101).
e14525 Background: MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal… 
Highly Cited
2008
Highly Cited
2008
Cell-specific Delivery of a Transforming Growth Factor-beta Type I Receptor Kinase Inhibitor to Proximal Tubular Cells for the Treatment of Renal Fibrosis
PurposeActivation of tubular epithelial cells by transforming growth factor-beta (TGF-β) plays an important role in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)